Establishment of a treatment for advanced hepatocellular carcinoma using a tri-functional silkworm antibody
| Project/Area Number |
24590986
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Hiroyuki 聖マリアンナ医科大学, 医学部, 准教授 (40332910)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Keywords | 三重特異性抗体 / 肝がん / カイコ抗体 / 抗体治療 |
|---|
| Outline of Final Research Achievements |
We were conducting research with the aim of development of antibody drug as an ideal treatment for advanced hepatocellular carcinoma. We used anti-FGFR-1 monoclonal antibody has been prepared, a significant anti-cancer effect against liver cancer cells in vitro and in vivo, have been clarified. Furthermore, so as to exert a more potent anti-cancer effect, a molecular alteration is added to the antibody to prepare a triple-specific human antibodies. Using a triple-specific human antibody that was created, we examined the ADCC activity in vitro and in vivo. To date, it has not been possible to obtain the expected ADCC activity. Currently, further subjected to molecular modifications are conducting research towards the silkworm antibody preparation.
|
Report
(4 results)
Research Products
(2 results)
